Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 184 participants.
Also called NCT02135029
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 184 participants
- Sponsor
- Registry
-
NCT02135029
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02135029. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (actual); primary completion 2015-11 (actual). Results posted on 2017-12-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
- Acronym
- SPIRE-SI
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Bococizumab (PF-04950615;RN316)
- Intervention (Drug)
- Atorvastatin
- Intervention (Other)
- Placebo for Bococizumab (PF-04950615;RN316)
- Intervention (Other)
- Placebo for atorvastatin
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct02135029- Content hash
ea207b443b81a6dc9b669f16bc38edbffeef751ccd673597f3c28642eb62595c